Nathan Smith - 02 Feb 2026 Form 4 Insider Report for CareDx, Inc. (CDNA)

Reporting relationship: Chief Financial Officer
Issuer ticker: CDNA
Reported as of: 02 Feb 2026
Net transaction value: -$78,801
SEC form: 4
Accepted by SEC: 04 Feb 2026, 16:23:01 UTC
Prior SEC filing: 11 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey Adam Novack, Attorney-in-Fact

Key filing fact

Nathan Smith filed Form 4 for CareDx, Inc. (CDNA) on 04 Feb 2026.

Key facts

This page summarizes Nathan Smith's Form 4 filing for CareDx, Inc. (CDNA).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 04 Feb 2026, 16:23.

Change

Previous filing in this sequence was filed on 11 Aug 2025.
Current net transaction value: -$78,801.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002079385 Primary reporting owner

SMITH NATHAN

Relationship: Chief Financial Officer
Address: C/O CAREDX, INC., 8000 MARINA BLVD., 4TH FLOOR, BRISBANE
Signature: /s/ Jeffrey Adam Novack, Attorney-in-Fact
Signature date: 04 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CDNA transaction

Common Stock

Award

Transaction value: $0
Shares: +33,000
Change %: +79%
Price: $0.000000
Shares after: 75,000
Date: 02 Feb 2026
Ownership: Direct
Footnotes: F1

CDNA transaction

Common Stock

Award

Transaction value: $0
Shares: +7,875
Change %: +10%
Price: $0.000000
Shares after: 82,875
Date: 02 Feb 2026
Ownership: Direct
Footnotes: F2

CDNA transaction

Common Stock

Tax liability

Transaction value: $78,801
Shares: -3,859
Change %: -4.7%
Price: $20.42
Shares after: 79,016
Date: 02 Feb 2026
Ownership: Direct
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The reported securities are represented by restricted stock units ("RSUs"), of which one-third will vest on April 6, 2027 and the remaining two-thirds will vest in equal quarterly installments thereafter on the last day of each of the subsequent eight quarters, rounded down to the nearest whole share until the last such installment, such that one-hundred percent of the RSUs will be vested on the third anniversary of April 6, 2027, subject to the Reporting Person's continuous employment on each applicable vesting date.

Footnote F2

The reported securities were subject to a performance restricted stock unit ("PRSU") award that was initially granted on February 1, 2025, and were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation and Human Capital Committee of the Issuer's Board of Directors on February 2, 2026.

Footnote F3

These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of PRSUs.